Product image of Ova-Mit (Clomifene Citrate) supplied by GNH India

Ova-Mit

Active Ingredient:
Clomifene Citrate
Origin:
EU

Ova-Mit (Clomifene Citrate)

Clomifene citrate, the active ingredient in Ova-Mit, is a selective estrogen receptor modulator presented as an oral tablet for oral use. It is employed to stimulate ovulation in women with anovulatory infertility, including polycystic ovary syndrome, and is indicated for use under medical supervision to improve chances of conception.

GNH India supplies Ova-Mit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory compliance across global markets.

Manufacturer / TM Owner

Remedica Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Clomifene citrate is a selective estrogen receptor modulator used in reproductive medicine to stimulate ovulation.

  • Anovulation due to polycystic ovary syndrome: induces ovulation and improves the likelihood of conception.
  • Infertility associated with anovulatory disorders: facilitates follicular development and increases pregnancy rates.
  • Clomiphene‑resistant ovulation induction (adjunct): may enhance ovarian response when combined with other fertility agents.

How It Works

  • Clomifene citrate binds to estrogen receptors in the hypothalamus, blocking negative feedback and increasing the release of gonadotropin‑releasing hormone. This elevation stimulates the pituitary to secrete higher levels of follicle‑stimulating hormone and luteinizing hormone, promoting follicular growth and ovulation in women with impaired endogenous estrogen signaling.

Side Effects

Clomifene citrate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Hot flashes: transient warmth and sweating.
  • Mood swings: emotional variability.
  • Nausea: mild gastrointestinal upset.
  • Breast tenderness: discomfort in breast tissue.
  • Headache: mild to moderate intensity.
  • Visual disturbances: blurred vision or spots.

Serious or Rare Side Effects

  • Ovarian hyperstimulation syndrome: excessive ovarian response with abdominal pain and fluid shift.
  • Multiple pregnancy: increased chance of twins or higher order gestations.
  • Ovarian cyst formation: cystic lesions that may require monitoring.
  • Thromboembolic events: rare clot formation.
  • Hepatic dysfunction: abnormal liver enzymes.
  • Allergic reactions: rash, itching, or anaphylaxis.

Precautions & Warnings

Before initiating therapy, clinicians should assess individual risk factors and monitor patients for adverse events.

  • Baseline ovarian assessment: evaluate follicular status via ultrasound.
  • Visual monitoring: advise patients to report any visual changes promptly.
  • Hepatic function: check liver enzymes in patients with known liver disease.
  • Pregnancy avoidance: ensure effective contraception until ovulation is confirmed.
  • Multiple pregnancy counseling: discuss the increased risk of twins or higher order gestations.
  • Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Clomifene citrate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Concomitant hormonal contraceptives: may reduce clomifene effectiveness.
  • Warfarin: clomifene may potentiate anticoagulant activity, increasing bleeding risk.
  • Strong CYP2D6 inhibitors: can affect clomifene metabolism and plasma levels.

Moderate Interactions (Monitor Closely)

  • Gonadotropins: combined use raises the risk of ovarian hyperstimulation.
  • Thyroid hormone therapy: may require dose adjustments based on thyroid status.
  • Selective serotonin reuptake inhibitors: can exacerbate mood‑related side effects.

Frequently Asked Questions

Ova-Mit contains clomifene citrate, a selective estrogen receptor modulator that is prescribed to induce ovulation in women with anovulatory infertility, such as polycystic ovary syndrome, and to support certain assisted reproductive technology cycles.

Clomifene citrate blocks estrogen receptors in the hypothalamus, reducing negative feedback and increasing gonadotropin‑releasing hormone release. This stimulates the pituitary to secrete more follicle‑stimulating hormone and luteinizing hormone, which promote follicular development and trigger ovulation.

The prescribing clinician determines the dose based on the patient’s response and clinical protocol. A common starting regimen is 50 mg taken orally once daily for five consecutive days, but the exact schedule must be set by a qualified healthcare professional.

Ova-Mit is contraindicated in pregnancy because it can affect fetal development. Limited data exist for breastfeeding, and the drug may pass into breast milk; therefore, use while nursing is generally discouraged unless the benefit outweighs the risk.

To request Ova-Mit, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for ovulation induction is letrozole, an aromatase inhibitor. Letrozole reduces estrogen synthesis, while clomifene citrate blocks estrogen receptors. Both aim to increase gonadotropin release, but letrozole may have a lower risk of multiple pregnancies and fewer estrogen‑related side effects.

Ova-Mit tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Ova-Mit is taken orally as a tablet, usually with water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to the menstrual cycle and any other fertility medications.

Serious risks include ovarian hyperstimulation syndrome, which can cause severe abdominal pain and fluid accumulation, and multiple pregnancy, which raises obstetric complications. Visual disturbances and rare thromboembolic events also require immediate medical attention.

Ova-Mit should not be used by women who are pregnant, have active liver disease, untreated ovarian cysts, uncontrolled thyroid disorders, or a known hypersensitivity to clomifene citrate or any tablet excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Clomifene Citrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT